Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.52 |
| ▸ | CTSK | P43235 | 11/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7787879 | 0.96 | CTSK (0.51) | CTSSCTSKCTSLCTSBP2RY2 | |
| SCHEMBL8517869 | 0.83 | CTSS (0.52) | CTSSCTSKCTSLCTSBP2RY2 | |
| SCHEMBL20817325 | 0.80 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL20817323 | 0.80 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL613038 | 0.79 | CTSK (0.51) | CTSSCTSKCTSLCTSBP2RY2 | |
| SCHEMBL17614512 | 0.79 | CTSK (0.67) | CTSSCTSK | |
| SCHEMBL5031623 | 0.79 | CTSK (0.51) | CTSSCTSKCTSLCTSBP2RY2 | |
| SCHEMBL28662338 | 0.79 | CTSK (0.51) | CTSSCTSKCTSLCTSBP2RY2 | |
| SCHEMBL19695765 | 0.79 | CTSK (0.51) | CTSSCTSKCTSLCTSBP2RY2 | |
| SCHEMBL6791457 | 0.79 | CTSK (0.51) | CTSSCTSKCTSLCTSBP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034342-A1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | OPLINGER JEFFREY ALAN (US) | 2001-10-25 | — | — | US | disclosed |
| US-6297276-B1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | GLAXOSMITHKLINE | 2001-10-02 | — | — | US | disclosed |
| US-6225305-B1 | Substituted urea and isothiorea derivatives as no synthase inhibitors | GLAXO WELLCOME INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0723438-A1 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995009619-A2 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034342-A1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | NOS1, NOS2, SLC14A1 | CTSS 1683/4885CTSK 4032/4885CTSL 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.